Faculty Collaboration Database

Evolution of treatment for diabetic nephropathy: historical progression from RAAS inhibition and onward. Postgrad Med 2011 Nov;123(6):166-79

Date

11/23/2011

Pubmed ID

22104465

DOI

10.3810/pgm.2011.11.2506

Scopus ID

2-s2.0-82155192728 (requires institutional sign-in at Scopus site)   10 Citations

Abstract

The past 2 decades have brought rapid advances in treatment options for chronic kidney disease; however, even with the best treatment, the decline of renal function and progression to end-stage renal disease (ESRD) continues in a significant number of patients. The prognosis of patients with diabetes and ESRD is grim, with < 50% of patients surviving beyond 5 years after diagnosis. Therefore, early recognition and optimal use of available interventions are essential, and research into newer therapeutic targets is needed. This article will review recent advances in our understanding of renal pathophysiology, summarize the evidence to date supporting current treatment options for diabetic nephropathy, and highlight new options that lie on the horizon for the treatment of diabetic kidney disease.

Author List

Blumenthal SS

Author

Samuel S. Blumenthal MD Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Angiotensin-Converting Enzyme Inhibitors
Diabetic Nephropathies
Glycation End Products, Advanced
Humans
Kidney Failure, Chronic
Mineralocorticoid Receptor Antagonists
Oxidative Stress
Renin-Angiotensin System
Transforming Growth Factor beta